Headache, Healthy
Conditions
Brief summary
Headaches are extremely common illnesses with a combined lifetime prevalence of 90-99% in Europe. Despite this high prevalence, there are persons who have never, in their whole life, encountered a headache. The aim of the study is to identify factors that protect against headache by studying multiomics in people who never have had a headache (headache resistant) versus non-resistant controls. The investigators will measure multiomic changes (transcriptomics and metabolomics) after headache provocation with isosorbide mononitrate. 3 blood samples, two for RNA and one for metabolomics are taken right before administration of isosorbide mononitrate, 3 hours after administration of isosorbide mononitrate and again 5 hours after administration of isosorbide mononitrate. The investigators hope to contribute with novelty to the current understanding of headache pathophysiology and development of more efficient treatment of headache.
Interventions
DRUGIsosorbide Mononitrate 60 MG Extended Release Oral Tablet [Imdur]
1 tablet Isosorbide Mononitrate 60 mg administrated orally.
OTHERBlood sample
3 blood samples from a periferal vein, two for RNA and one for metabolomics are taken right before administration of isosorbide mononitrate, 3 hours after administration of isosorbide mononitrate and again 5 hours after administration of isosorbide mononitrate.
Sponsors
Danish Headache Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Intervention model description
Case-control study.
Eligibility
Sex/Gender
MALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Headache resistant and non-resistant male participants from the Danish Blood Donor Study. * Weight: 45 kg to 95 kg
Exclusion criteria
* Daily consumption of any medication. * Consumption of any medication less than 12 hours prior to the study day. * Headache on the study day or 48 hours prior to the study day. * Amnestic or clinical signs of hypertension (systolic blood pressure \>150 mmHg and/or diastolic blood pressure \>100 mmHg) or hypotension (systolic blood pressure \<90 mmHg and/or diastolic blood pressure \<50 mmHg). * Any severe cardiovascular disease, including cerebrovascular illness. * Amnestic or clinical signs of current mental illness. * Amnestic or clinical signs of current substance or drug abuse. * Amnestic or clinical signs of any illness the responsible doctor considers relevant for participation in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Transcriptomic changes | 5 hours | Difference in RNA expression between cases and controls after headache provocation by Isosorbide Mononitrate. |
| Metabolomic changes | 5 hours | Difference in metabolites between cases and controls after headache provocation by Isosorbide Mononitrate. |
Countries
Denmark
Outcome results
None listed